Related references
Note: Only part of the references are listed.Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Tanya Siddiqi et al.
BLOOD (2022)
Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis
Wenjing Luo et al.
BMC CANCER (2022)
CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma
Rui Liu et al.
HUMAN GENE THERAPY (2022)
Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
Koji Kato et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)
Aging and Clonal Behavior of Hematopoietic Stem Cells
Masayuki Yamashita et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Caron A. Jacobson et al.
LANCET ONCOLOGY (2022)
Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system
Huan Zhang et al.
LEUKEMIA & LYMPHOMA (2022)
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Nathan Hale Fowler et al.
NATURE MEDICINE (2022)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients
Lei Fan et al.
FRONTIERS OF MEDICINE (2022)
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
Jordan Gauthier et al.
BLOOD (2022)
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma
Ying Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial
Yajing Zhang et al.
LEUKEMIA (2022)
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial
Sattva S. Neelapu et al.
NATURE MEDICINE (2022)
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Leila Amini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Preferential expansion of CD8+CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL
Aimee C. Talleur et al.
BLOOD ADVANCES (2022)
Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia
Saar Gill et al.
BLOOD ADVANCES (2022)
Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma
Jennifer M. Logue et al.
HAEMATOLOGICA (2021)
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
M-L Schubert et al.
ANNALS OF ONCOLOGY (2021)
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies
Valentin Ortiz-Maldonado et al.
MOLECULAR THERAPY (2021)
Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial
Stephan Kadauke et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China
Zhitao Ying et al.
CANCER MEDICINE (2021)
Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
John H. Baird et al.
BLOOD ADVANCES (2021)
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies
Sarah J. Nagle et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Yongxian Hu et al.
CLINICAL CANCER RESEARCH (2021)
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
Shaun Cordoba et al.
NATURE MEDICINE (2021)
Immunogenicity of CAR T cells in cancer therapy
Dimitrios L. Wagner et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
Michael Maschan et al.
NATURE COMMUNICATIONS (2021)
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
Bijal D. Shah et al.
BLOOD (2021)
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
Andrew Schaefer et al.
CANCER MANAGEMENT AND RESEARCH (2021)
CAR T-Cell Therapy in Hematological Malignancies
Theresa Haslauer et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia
Regina M. Myers et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Claire Roddie et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel et al.
NATURE MEDICINE (2021)
A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
Xiaoqian Liu et al.
TRANSLATIONAL ONCOLOGY (2021)
Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives
Roman P. Labbe et al.
VIRUSES-BASEL (2021)
CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
Guoqing Wei et al.
CANCER IMMUNOLOGY RESEARCH (2021)
Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL
Ming Sun et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
Ying Zhang et al.
FRONTIERS IN ONCOLOGY (2021)
Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
Cuicui Lyu et al.
FRONTIERS IN ONCOLOGY (2021)
Recent advances and discoveries in the mechanisms and functions of CAR T cells
Rebecca C. Larson et al.
NATURE REVIEWS CANCER (2021)
Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients
Ying Wang et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies
Na Wang et al.
BLOOD (2020)
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL
Jing Pan et al.
BLOOD (2020)
Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia
Gang Heng et al.
CLINICAL CANCER RESEARCH (2020)
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
Jennifer N. Brudno et al.
NATURE MEDICINE (2020)
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center
Pierre Sesques et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Phase II trial of co-administration of CD19-and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma
Wei Sang et al.
CANCER MEDICINE (2020)
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Chelsea C. Pinnix et al.
BLOOD ADVANCES (2020)
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
Tania Jain et al.
BLOOD ADVANCES (2020)
Recent advances in CAR-T cell engineering
Ruihao Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma
Kitsada Wudhikarn et al.
BLOOD CANCER JOURNAL (2020)
Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
Runxia Gu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah et al.
NATURE MEDICINE (2020)
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
Xuan Zhou et al.
FRONTIERS IN IMMUNOLOGY (2020)
A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma
Xinfeng Chen et al.
IMMUNOTHERAPY (2020)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
Mechanisms of resistance to CAR T cell therapy
Nirali N. Shah et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Nirav N. Shah et al.
FRONTIERS IN ONCOLOGY (2019)
A safe and potent anti-CD19 CAR T cell therapy
Zhitao Ying et al.
NATURE MEDICINE (2019)
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma
Austin J. Sim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma
Zi-Xun Yan et al.
CLINICAL CANCER RESEARCH (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma
Zhitao Ying et al.
MOLECULAR THERAPY-ONCOLYTICS (2019)
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J. Curran et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL
Mark B. Geyer et al.
JCI INSIGHT (2019)
In Vivo Expansion and Antitumor Activity of Coinfused CD28-and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia
Zhi Cheng et al.
MOLECULAR THERAPY (2018)
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy
Mark B. Geyer et al.
MOLECULAR THERAPY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas
Carlos A. Ramos et al.
MOLECULAR THERAPY (2018)
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Gunilla Enblad et al.
CLINICAL CANCER RESEARCH (2018)
Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
Yongxian Hu et al.
CLINICAL CANCER RESEARCH (2017)
Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Cameron J. Turtle et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Smoking and the outcome of infection
R. Huttunen et al.
JOURNAL OF INTERNAL MEDICINE (2011)
Methodological index for non-randomized studies (MINORS):: Development and validation of a new instrument
K Slim et al.
ANZ JOURNAL OF SURGERY (2003)